Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.42 |
| ▸ | ARG2 | P78540 | 2/20 | 0.42 |
| ▸ | CTSC | P53634 | 10/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27999407 | 0.77 | SLC6A2 (0.46) | ARG1ARG2CTSCHTTCTBP2 | |
| SCHEMBL1818900 | 0.77 | SLC6A2 (0.46) | ARG1ARG2CTSCHTTCTBP2 | |
| SCHEMBL4637455 | 0.69 | TSHR (0.36) | CTSCGAA | |
| SCHEMBL4802125 | 0.68 | ARG1 (0.34) | ARG1ARG2HTTGAA | |
| SCHEMBL4840142 | 0.66 | CYP3A4 (0.44) | CTSCSAE1UBA2 | |
| SCHEMBL4798320 | 0.66 | CYP3A4 (0.44) | CTSCSAE1UBA2 | |
| SCHEMBL1818451 | 0.63 | SLC6A2 (0.48) | — | |
| SCHEMBL7440413 | 0.63 | ALDH1A1 (0.41) | — | |
| SCHEMBL29352303 | 0.63 | SLC6A2 (0.48) | — | |
| SCHEMBL1819168 | 0.62 | SLC6A2 (0.44) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375237-B2 | Pyrrolizine compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20060052434-A1 | Pyrrolizine compounds useful as anti-inflammatory agents | CEREP S.A. (FR) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052434-A1 | Pyrrolizine compounds useful as anti-inflammatory agents | NFKBIA, TNF, NFKB1 | ARG1 6/4885ARG2 54/4885CTSC 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.